CIDARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.722 USD | -0.03% |
|
-16.44% | -9.07% |
| Apr. 11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
| Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Financials (USD)
| Sales 2023 * | 57.85M | Sales 2024 * | 21.07M | Capitalization | 65.43M |
|---|---|---|---|---|---|
| Net income 2023 * | -27M | Net income 2024 * | -56M | EV / Sales 2023 * | 1.13 x |
| Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 3.11 x |
| P/E ratio 2023 * |
-2.35
x | P/E ratio 2024 * |
-1.25
x | Employees | 73 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 92.47% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cidara Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -0.03% | ||
| 1 week | -16.44% | ||
| Current month | -21.52% | ||
| 1 month | +4.11% | ||
| 3 months | -3.73% | ||
| 6 months | -16.06% | ||
| Current year | -9.07% |
1 week
0.69
0.88
1 month
0.691.22
Current year
0.631.22
1 year
0.591.48
3 years
0.402.39
5 years
0.404.45
10 years
0.4019.13
| Managers | Title | Age | Since |
|---|---|---|---|
Jeffrey Stein
CEO | Chief Executive Officer | 69 | 13-12-31 |
Preetam Shah
DFI | Director of Finance/CFO | 51 | 21-08-31 |
Les Tari
CTO | Chief Tech/Sci/R&D Officer | 57 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 14-03-31 |
| Director/Board Member | 69 | 14-03-31 | |
Jeffrey Stein
CEO | Chief Executive Officer | 69 | 13-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.722 | -0.03% | 274,327 |
| 24-04-17 | 0.7222 | -1.07% | 429,848 |
| 24-04-16 | 0.73 | -11.48% | 1,269,963 |
| 24-04-15 | 0.8247 | +1.81% | 305,123 |
| 24-04-12 | 0.81 | -6.26% | 538,466 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Companyâs primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couplesâ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.722
USD
Average target price
4.667
USD
Spread / Average Target
+546.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.07% | 65.43M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.43% | 21.66B | |
| -18.35% | 20.77B | |
| -8.65% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- CDTX Stock
